Rachel J Gibson1,2, Ysabella Z A van Sebille1,2, Hannah R Wardill3,4,5, Anthony Wignall2, Joseph Shirren2, Imogen A Ball2, Nicole Williams2, Kiara Wanner2, Joanne M Bowen2. 1. Division of Health Sciences, University of South Australia, Adelaide, South Australia, Australia. 2. Discipline of Physiology, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. 3. Discipline of Physiology, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia, hannah.wardill@adelaide.edu.au. 4. Centre for Nutrition and Gastrointestinal Disease, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia, hannah.wardill@adelaide.edu.au. 5. Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands, hannah.wardill@adelaide.edu.au.
Abstract
BACKGROUND: The common cytotoxic mechanisms that underpin chemoefficacy and toxicity have hampered efforts to deliver effective supportive care interventions, particularly for gastrointestinal (GI) toxicity. Matrix metalloproteinases (MMPs) have been implicated in both tumor growth and GI toxicity, and as such MMP inhibitors present as a novel therapeutic avenue to simultaneously enhance treatment efficacy and reduce toxicity. OBJECTIVES: The aim of this study was to determine the efficacy of an MMP-9/12 inhibitor, AZD3342, on tumor growth and GI toxicity in a rat model. METHODS: Female tumor-bearing Dark Agouti rats (n = 90) were divided into 4 groups: vehicle control; methotrexate (MTX); AZD3342, and MTX + AZD3342. Tumors were measured daily (for 5 days) using digital calipers. GI toxicity was assessed using well-established clinical markers (diarrhea/weight loss), histopathological analysis, and functional assessment of intestinal barrier permeability. RESULTS: AZD3342 delayed the onset of severe diarrhea by 1 day (vs. MTX) but was unable to improve the overall severity of diarrhea. No changes were detected in tissue morphology or intestinal barrier function. AZD3342 alone suppressed tumor growth (p = 0.003 vs. vehicle) but did not enhance the efficacy of MTX. CONCLUSIONS: This study showed partial efficacy of AZD3342 in reducing tumor growth and delaying the onset of severe diarrhea caused by MTX in rats. We suggest further studies be undertaken targeting appropriate scheduling of AZD3342 as well as investigating different cytotoxic therapies that strongly activate MMP signaling.
BACKGROUND: The common cytotoxic mechanisms that underpin chemoefficacy and toxicity have hampered efforts to deliver effective supportive care interventions, particularly for gastrointestinal (GI) toxicity. Matrix metalloproteinases (MMPs) have been implicated in both tumor growth and GI toxicity, and as such MMP inhibitors present as a novel therapeutic avenue to simultaneously enhance treatment efficacy and reduce toxicity. OBJECTIVES: The aim of this study was to determine the efficacy of an MMP-9/12 inhibitor, AZD3342, on tumor growth and GI toxicity in a rat model. METHODS: Female tumor-bearing Dark Agouti rats (n = 90) were divided into 4 groups: vehicle control; methotrexate (MTX); AZD3342, and MTX + AZD3342. Tumors were measured daily (for 5 days) using digital calipers. GI toxicity was assessed using well-established clinical markers (diarrhea/weight loss), histopathological analysis, and functional assessment of intestinal barrier permeability. RESULTS:AZD3342 delayed the onset of severe diarrhea by 1 day (vs. MTX) but was unable to improve the overall severity of diarrhea. No changes were detected in tissue morphology or intestinal barrier function. AZD3342 alone suppressed tumor growth (p = 0.003 vs. vehicle) but did not enhance the efficacy of MTX. CONCLUSIONS: This study showed partial efficacy of AZD3342 in reducing tumor growth and delaying the onset of severe diarrhea caused by MTX in rats. We suggest further studies be undertaken targeting appropriate scheduling of AZD3342 as well as investigating different cytotoxic therapies that strongly activate MMP signaling.
Keywords:
AZD3342; Adverse drug reactions; Breast cancer; Diarrhea; Gastrointestinal toxicity; Intervention; Matrix metalloproteinases; Methotrexate; Mucositis; Rat model
Authors: Peter-Martin Krarup; Mikkel Eld; Lars Nannestad Jorgensen; Mark Berner Hansen; Magnus S Ågren Journal: Int J Colorectal Dis Date: 2017-07-17 Impact factor: 2.571
Authors: E I Heath; S O'Reilly; R Humphrey; P Sundaresan; R C Donehower; S Sartorius; M J Kennedy; D K Armstrong; M A Carducci; J M Sorensen; K Kumor; S Kennedy; L B Grochow Journal: Cancer Chemother Pharmacol Date: 2001-10 Impact factor: 3.333
Authors: Natasha B Leighl; Luis Paz-Ares; Jean-Yves Douillard; Christian Peschel; Andrew Arnold; Alain Depierre; Armando Santoro; Daniel C Betticher; Ulrich Gatzemeier; Jacek Jassem; Jeffrey Crawford; Dongsheng Tu; Andrea Bezjak; Jeffrey S Humphrey; Maurizio Voi; Susan Galbraith; Katherine Hann; Lesley Seymour; Frances A Shepherd Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Noor Al-Dasooqi; Joanne M Bowen; Rachel J Gibson; Richard M Logan; Andrea M Stringer; Dorothy M Keefe Journal: Int J Exp Pathol Date: 2011-04-05 Impact factor: 1.925
Authors: Hannah R Wardill; Rachel J Gibson; Ysabella Z A Van Sebille; Kate R Secombe; Janet K Coller; Imogen A White; Jim Manavis; Mark R Hutchinson; Vasiliki Staikopoulos; Richard M Logan; Joanne M Bowen Journal: Mol Cancer Ther Date: 2016-03-29 Impact factor: 6.261
Authors: Hannah R Wardill; Raymond J Chan; Alexandre Chan; Dorothy Keefe; Samuel P Costello; Nicolas H Hart Journal: Support Care Cancer Date: 2022-03-10 Impact factor: 3.359